worldwid
reportedli
million
sever
million
sever
case
lower
respiratori
tract
infect
lrti
children
respiratori
syncyti
viru
rsv
common
contributor
respiratori
infect
caus
bronchiol
pneumonia
chronic
obstruct
pulmonari
infect
peopl
age
affect
mainli
children
elderli
along
viral
infect
lead
high
mortal
morbid
recent
global
survey
suggest
rsv
preval
throughout
year
tropic
region
globe
incid
peak
winter
wide
rang
persist
depend
geograph
topolog
rsv
report
preval
lower
respiratori
tract
pathogen
distribut
worldwid
includ
countri
develop
develop
world
major
countri
rsv
season
outbreak
includ
usa
canada
cambodia
mexico
uruguay
brazil
peru
franc
finland
norway
sweden
latvia
denmark
germani
netherland
ireland
itali
turkey
iran
saudi
arabia
australia
new
zealand
china
korea
hong
kong
japan
india
pakistan
bangladesh
nepal
taiwan
vietnam
myanmar
thailand
madagascar
kenya
zambia
nigeria
columbia
data
human
rsv
describ
literatur
year
seem
unchang
significantli
indic
sever
rsv
urgent
concern
address
issu
estim
billion
us
dollar
per
year
econom
cost
viral
lower
respiratori
tract
infect
children
rsv
paramyxoviru
belong
genu
pneumoviru
rsv
envelop
nonseg
neg
singl
strand
linear
rna
genom
viru
figur
rsv
genom
kb
gene
encod
protein
two
open
read
frame
gene
gene
includ
nonstructur
protein
type
interferon
inhibitor
l
rna
polymeras
n
nucleoprotein
p
phosphoprotein
cofactor
l
matrix
protein
requir
transcript
sh
small
hydrophob
protein
g
glycoprotein
f
fusion
protein
neg
strand
rna
genom
viru
rsv
packag
polymeras
nucleocapsid
protein
fusion
protein
f
indispens
viral
attach
host
entri
host
cell
although
g
protein
respons
preliminari
attach
f
protein
necessari
fusion
bud
spread
viru
attach
host
cell
rsv
fuse
host
cell
membran
use
f
protein
helix
coiledcoil
bundl
f
protein
mechan
characterist
found
paramyxovirida
member
although
detail
mechan
rsv
infect
fulli
understood
accept
mechan
entri
nucleocapsid
host
cell
mediat
f
protein
clathrin
mediat
endocytosi
rna
first
convert
plu
strand
serv
templat
replic
wherea
transcript
rna
genom
transcrib
mrna
protein
synthesi
without
intermedi
almost
children
year
age
rsv
infect
lead
death
per
year
approxim
infant
children
first
exposur
rsv
sign
symptom
bronchiol
pneumonia
symptom
includ
rhinorrhea
lowgrad
fever
cough
wheez
symptom
adult
may
includ
common
cold
rhinorrhea
sore
throat
cough
malais
headach
fever
also
lead
exacerb
symptom
sever
pneumonia
elderli
especi
resid
nurs
home
usual
children
show
symptom
within
day
infect
recov
week
serv
carrier
viru
week
rsv
infect
children
nosocomi
origin
associ
higher
mortal
communityacquir
ill
preexist
morbid
sever
rsv
diseas
risk
hover
elderli
adult
chronic
heart
lung
diseas
weaken
immun
system
rsv
infect
provok
last
immun
therefor
reinfect
common
recent
rsv
infect
report
account
hospit
mortal
elderli
peopl
rsv
account
sever
lower
respiratori
tract
infect
includ
chronic
lung
diseas
system
comorbid
even
death
present
specif
treatment
rsv
infect
ever
sinc
first
discoveri
current
food
drug
administr
fda
approv
prophylact
drug
rsv
includ
palivizumab
ribavirin
administ
along
symptomat
treatment
drug
support
care
current
techniqu
use
diagnosi
rsv
includ
elisa
direct
immunofluoresc
western
blot
pcr
realtim
pcr
diagnosi
treatment
scenario
significantli
chang
advent
advanc
techniqu
indepth
understand
rsv
biolog
execut
clinic
develop
practic
requir
extens
studi
time
review
present
recent
advanc
diagnosi
prevent
treatment
rsv
figur
enzymelink
immunosorb
assay
elisa
enzym
facilit
colorimetr
detect
specif
proteinantibodi
complex
elisa
extens
use
detect
variou
protein
low
concentr
differ
sampl
type
thu
make
clinic
signific
routin
diagnosi
pathogen
elisa
rsv
detect
mainli
base
target
rsv
f
protein
antigen
recent
sever
modif
classic
elisa
techniqu
effici
develop
employ
detect
rsv
sensit
elisa
increas
use
high
affin
antirsv
f
antibodi
peptid
deriv
motavizumab
motavizumab
high
affin
antibodi
base
therapeut
rsv
bind
rsv
f
protein
howev
disapprov
fda
due
higher
hypersensit
patient
receiv
motavizumab
compar
palivizumab
motavizumab
also
caus
urticaria
presum
better
bind
target
convent
f
protein
elisa
method
could
prove
effect
f
protein
elisa
due
higher
sensit
degrad
motavizumab
simpl
thin
layer
amperometr
enzym
immunoassay
rsv
detect
earli
minut
low
cost
compar
sensit
realtim
pcr
immunofluoresc
assay
assay
base
develop
doubl
layer
sandwich
method
similar
elisa
involv
polystyren
microarray
slide
coat
monoclon
antibodi
captur
antigen
rsv
antigenantibodi
complex
detect
hors
radish
peroxidas
conjug
secondari
antibodi
screen
print
electrochem
cell
coat
substrat
present
immunofluoresc
one
common
rapid
rsv
detect
techniqu
use
antigen
detect
fluoresc
tag
antibodi
direct
fluoresc
antibodi
assay
dfa
standard
detect
techniqu
use
decad
rsv
detect
techniqu
often
compar
dfa
evalu
effici
indirect
assay
use
secondari
fluoresc
tag
antibodi
anoth
option
dfa
current
mani
molecular
techniqu
sensit
reliabl
dfa
dfa
wide
use
rsv
detect
clinic
sampl
due
eas
rapid
sensit
specif
dfa
subject
varianc
success
techniqu
depend
numer
factor
mainli
skill
technician
natur
sampl
studi
show
dfa
could
detect
rsv
sensit
specif
respect
posit
predict
valu
neg
predict
valu
dfa
reliabl
techniqu
rsv
detect
patient
test
within
first
day
onset
symptom
sensit
decreas
test
day
onset
symptom
dfa
detect
rsv
alon
multival
test
respiratori
virus
influenza
b
virus
parainfluenza
viru
type
adenoviru
use
simulfluor
respiratori
screen
assay
direct
visual
antigenantibodi
complex
often
refer
optic
immunoassay
oia
use
qualit
detect
streptococcu
influenza
viru
visual
immunocomplex
enhanc
immobil
special
reflect
surfac
antigenantibodi
complex
form
thin
layer
chang
reflect
properti
surfac
techniqu
simpl
rapid
sensit
low
ng
antibodi
per
ml
also
detect
oia
use
detect
rsv
sensit
specif
posit
neg
predict
valu
respect
though
oia
offer
rapid
costeffect
rsv
detect
recommend
neg
result
oia
confirm
test
later
flow
immunoassay
lfia
immunochromatograph
techniqu
known
rapid
detect
rsv
nasal
wash
nasal
aspir
later
flow
antigenantibodi
complex
substrat
matrix
reach
reaction
area
result
format
color
band
indic
presenc
antigen
specimen
mani
lfia
kit
like
remel
xpect
binax
rsv
bd
directigen
ez
rsv
quicklab
rsv
test
rsv
respistrip
sensit
specif
normal
respect
vari
per
manufactur
modif
lfia
may
includ
colloid
gold
conjug
antibodi
specif
rsv
matrix
trap
antigen
assist
gold
mediat
reaction
color
band
develop
loopmedi
isotherm
amplif
lamp
nucleic
acid
base
detect
method
use
bacteri
viral
pathogen
use
rna
virus
addit
step
cdna
synthesi
requir
commonli
design
revers
transcript
lamp
rtlamp
lamp
consist
pair
primer
specif
cdna
amplifi
autocycl
strand
displac
activ
dna
polymeras
gener
reaction
time
hour
suffici
monitor
realtim
turbidimet
result
product
also
view
agaros
gel
electrophoresi
method
distinguish
rsv
strain
b
upon
restrict
digest
product
altern
rsv
strain
b
detect
design
specif
primer
set
effici
rtlamp
test
rsv
detect
nasopharyng
aspir
compar
viral
isol
enzym
immunoassay
immunochromatograph
assay
realtim
pcr
rtlamp
sensit
among
method
test
except
realtim
pcr
also
rtlamp
specif
rsv
react
respiratori
pathogen
like
rna
virus
dna
viru
bacteria
although
method
rapid
requir
turbidimet
make
slightli
inconveni
costeffect
detect
techniqu
develop
chemistri
lamp
made
possibl
get
rid
turbidimet
possibl
visual
detect
presenc
pathogen
test
sampl
lamp
refer
colorimetr
detect
loopmedi
isotherm
amplif
reaction
due
incorpor
dye
chemistri
aid
visual
detect
wang
et
al
develop
rtlamp
assay
detect
human
metapneumovirus
includ
rhinoviru
rsv
influenza
viru
detect
low
ten
viral
rna
copi
better
effici
rtpcr
possibl
detect
rsv
b
strain
nasopharyng
specimen
use
multiplex
lamp
mlamp
minut
mlamp
sensit
specif
compar
pcr
applic
pcr
ubiquit
made
diagnosi
pathogen
tremend
rapid
sensit
rsv
usual
challeng
detect
due
poor
viral
titer
sensit
antigen
base
detect
method
thu
pcr
base
method
develop
compar
serolog
cultur
base
detect
method
adult
respiratori
infect
pcr
method
base
revers
transcriptionnest
pcr
techniqu
involv
outer
inner
primer
design
f
gene
rsv
strain
two
day
procedur
sensit
method
faster
compar
convent
cultur
method
usual
take
day
result
faster
treatment
although
convent
revers
transcriptasepcr
rtpcr
sensit
compar
cultur
method
suffer
lower
sensit
problem
obviat
develop
realtim
pcr
base
method
realtim
pcr
far
sensit
method
detect
diagnosi
wide
array
pathogen
includ
rsv
sever
studi
conduct
develop
realtim
pcr
assay
rsv
detect
especi
rtpcr
one
studi
rapid
sensit
specif
method
devis
base
taqman
realtim
pcr
detect
rsv
rsv
b
strain
primer
probe
set
design
nucleocapsid
gene
n
sensit
method
found
pfu
plaqu
form
unit
two
copi
mrna
rsv
wherea
sensit
rsv
b
pfu
nine
mrna
copi
method
fast
effici
diagnosi
perform
within
hour
procur
sampl
similar
assay
base
realtim
pcr
develop
employ
detect
rsv
bronchoalveolar
lavag
bal
lung
transplant
patient
patient
respiratori
infect
assay
design
base
rsv
n
gene
first
involv
screen
step
rsv
posit
sampl
use
sybr
green
base
assay
follow
quantit
realtim
pcr
use
taqman
base
assay
cost
effect
also
assay
develop
detect
rsv
b
subgroup
separ
assay
found
posit
transplant
patient
thu
indic
possibl
associ
rsv
infect
lung
transplant
toler
realtim
pcr
base
rsv
n
gene
also
use
quantifi
rsv
nasal
aspir
children
method
one
log
sensit
convent
cultur
method
realtim
pcr
assay
result
posit
wherea
immunofluoresc
assay
cultur
method
posit
surprisingli
rsv
gapdh
ratio
differ
children
sever
nonsever
infect
rais
confus
correl
viral
load
sever
infect
due
intens
viral
replic
genet
suscept
host
immun
respons
thu
make
necessari
consid
factor
besid
viral
load
similar
assay
develop
detect
rsv
use
primerprob
set
rsv
f
gene
compar
analysi
made
nest
rtpcr
realtim
pcr
elisa
wherein
realtim
pcr
sensit
convent
nest
pcr
thu
make
applic
clinic
sampl
addit
realtim
pcr
perform
two
step
increas
sensit
sampl
method
rapid
result
obtain
hour
upon
receiv
sampl
sever
report
also
emphas
applic
realtim
pcr
detect
rsv
immunocompromis
patient
besid
rsv
f
n
gene
rsv
matrix
gene
polymeras
gene
also
use
detect
rsv
children
latter
method
abil
quantifi
classifi
rsv
high
effici
rapid
howev
sensit
techniqu
reli
age
patient
multiplex
pcr
approach
use
detect
subtyp
rsv
human
influenza
viru
simultan
mani
respiratori
virus
could
detect
method
base
primer
set
hemagglutinin
nucleoprotein
gene
influenza
viru
nucleocapsid
protein
gene
rsv
found
rapid
specif
sensit
howev
method
suffer
drawback
could
distinguish
rsv
b
method
could
prove
signific
respiratori
outbreak
surveil
situat
multiplex
realtim
pcr
assay
commerci
simplexa
flu
ab
rsv
kit
differenti
influenza
viru
influenza
b
viru
rsv
use
likewis
recent
rapid
sensit
detect
assay
rsv
respiratori
virus
develop
idaho
technolog
christen
filmarray
idaho
technolog
salt
lake
citi
ut
automat
realtim
molecular
station
capabl
nucleic
acid
extract
initi
revers
transcript
multiplex
pcr
follow
singleplex
secondstag
pcr
reaction
specif
viru
detect
correl
gene
express
signatur
diseas
progress
patient
individu
genet
profil
possibl
comprehens
understand
interpret
dynam
biomeinteract
lung
would
result
effici
therapi
respiratori
diseas
via
concept
person
medicin
wherein
microarray
find
applic
microarray
miniatur
assay
platform
highdens
array
immobil
dna
protein
hybrid
sampl
biomolecul
correspond
dna
protein
chip
detect
allow
determin
varieti
analyt
present
sampl
singl
experi
microarray
prove
robust
reliabl
tool
understand
echelon
genom
transcriptom
proteom
implement
microarray
metagenom
approach
serv
rapid
viru
identif
microarray
base
identif
character
virus
clinic
diagnost
possibl
design
oligonucleotid
probe
use
sequenc
data
avail
public
databas
approach
capabl
discov
novel
virus
even
though
conserv
gene
target
sequenc
case
respiratori
diseas
execut
collect
bronchoalveolar
lavag
enrich
nucleas
treatment
follow
filtrat
extract
total
nucleic
acid
nucleic
acid
amplifi
random
primingbas
method
refer
sequenc
independ
singl
primer
amplif
give
nearfulllength
read
genom
rna
dna
virus
could
compar
known
virus
use
design
oligom
microarray
thu
sequenc
coupl
microarray
power
high
throughput
diagnost
tool
util
metagenom
base
strategi
broadspectrum
diagnost
assay
use
microarray
demonstr
screen
virus
like
rhino
viru
parainfluenza
viru
sendai
viru
polioviru
adenoviru
rsv
clinic
sampl
wellknown
exampl
virochip
panvir
microarray
design
simultan
detect
known
virus
compar
superior
sensit
specif
convent
diagnost
similarli
influenza
microarray
microarray
rapid
identif
influenza
viru
subtyp
develop
procedur
simpl
follow
step
includ
rna
extract
clinic
sampl
subsequ
revers
transcript
secondstrand
cdna
synthesi
pcr
amplif
randomli
prime
cdna
hybrid
nucleic
acid
probe
done
fluoresc
dye
altern
method
electrochem
detect
latter
method
reli
redox
reaction
gener
electr
current
array
measur
incorpor
fluoresc
dye
hybrid
microarray
empow
specif
algorithm
match
diagnost
need
lead
final
critic
step
scan
analysi
gene
involv
pathway
neuroact
ligandreceptor
interact
signal
ubiquitin
mediat
proteolysi
jakstat
signal
cytokinecytokin
receptor
interact
hematopoiet
cell
lineag
cell
cycl
apoptosi
cancer
upregul
rsvinfect
cell
rsv
infect
upregul
gene
h
h
respect
gene
common
instanc
moreov
gene
downregul
h
h
respect
gene
respiratori
diseas
biomark
like
pten
also
detect
rsv
infect
sign
symptom
render
partial
consequ
host
pathogen
interact
transcript
profil
better
exemplifi
microarray
transcript
profil
rsv
infect
mice
lung
lymph
node
show
gene
express
antigen
process
inflamm
respons
higher
lung
day
rsv
infect
day
gene
express
profil
shortli
rsv
infect
account
biomark
scale
diagnost
vitro
vivo
profil
sometim
dna
microarray
confer
util
specif
investig
case
person
medicin
wherein
manifest
diseas
occur
transcript
level
situat
may
aris
complic
rsv
associ
disord
like
asthma
protein
abund
function
biomolecul
reflect
physiolog
patholog
state
organ
protein
microarray
profil
option
access
situat
protein
microarray
analyt
function
applic
studi
proteinprotein
proteindna
proteinligand
interact
featur
enabl
profil
immun
respons
thu
import
diagnost
biomark
discoveri
protein
microarray
serv
rapid
sensit
simpl
tool
largescal
identif
viralspecif
antibodi
sera
extens
studi
done
sar
pandem
use
coronaviru
protein
microarray
screen
antibodi
human
sera
sampl
accuraci
least
sensit
specif
avail
elisa
test
thu
system
enorm
potenti
use
epidemiolog
tool
screen
viral
infect
mass
spectroscopi
ms
becom
method
choic
molecular
investig
pathogen
reliabl
reinforc
due
wellcharacter
sequenc
inform
nucleic
acid
protein
even
intact
virus
pragmat
usag
ms
possibl
coupl
variou
chromatographi
affinitybas
techniqu
combin
affin
base
viral
detent
nucleic
acid
base
ms
serv
solut
low
detect
limit
affinitybas
method
employ
nanotechnolog
use
find
trace
target
pathogen
improv
detect
limit
pcr
amplif
pathogen
nucleic
acid
combin
ms
use
substitut
ms
advantag
rapid
identif
multipl
virus
time
even
identifi
protein
modif
statu
ms
longer
confin
proteom
base
analysi
ms
base
genom
becom
common
practic
sever
variat
ms
like
matrixassist
laser
desorptionion
mass
spectroscopi
maldim
surfaceenhanc
laser
desorptionion
mass
spectroscopi
seldim
bioaerosol
mass
spectrometri
bam
pyrolysi
ga
chromatographi
mass
spectrometri
pygcm
capillari
electrophores
liquid
chromatographi
mass
spectrometri
lcm
exampl
use
identif
pathogen
ms
techniqu
promis
robust
practic
applic
pathogen
detect
electrospray
ioniz
mass
spectrometri
esim
figur
notabl
esim
global
surveil
influenza
viru
accomplish
sampath
et
al
coupl
ms
reversetranscript
pcr
rtpcr
studi
correctli
identifi
mammalian
avian
influenza
isol
repres
differ
h
n
type
includ
avian
isol
analysi
show
sensit
specif
identif
clinic
human
respiratori
specimen
collect
sevenyear
period
speci
subtyp
level
surveil
sampl
influenza
viru
incid
show
evid
new
genotyp
strain
studi
also
suggest
approxim
mix
viral
quasispeci
sampl
provid
insight
viral
evolut
studi
led
number
rtpcresim
base
detect
method
rsv
relat
respiratori
virus
like
influenza
b
parainfluenza
type
adenovirida
type
coronavirida
human
bocaviru
human
metapneumoviru
screen
assay
accuraci
compar
convent
clinic
virolog
assay
pathogen
undetect
tradit
clinic
virolog
method
could
success
detect
advantag
rtpcresim
platform
abil
determin
quantiti
pathogen
detail
pathogen
character
detect
multipl
pathogen
high
sensit
effici
immunopcr
combin
elisa
pcr
use
wide
detect
variou
bacteri
viral
antigen
lower
titer
meagr
zepto
mole
perez
et
al
report
modif
immunopcr
use
gold
nanoparticl
rsv
detect
target
extract
enhanc
use
magnet
microparticl
mmp
function
antirsv
antibodi
captur
antigen
rsv
mmprsv
complex
counter
gold
nanoparticl
function
palivizumab
synagi
antirsv
f
protein
antibodi
dna
sequenc
partial
hybrid
tag
dna
sequenc
faunp
mmprsvfaunp
complex
heat
releas
partial
hybrid
tag
dna
sequenc
quantifi
supernat
realtim
pcr
modif
enabl
detect
rsv
even
pfuml
assay
offer
improv
limit
detect
elisa
improv
detect
compar
realtim
rtpcr
live
cell
imag
provid
benefit
effect
diagnosi
treatment
capabl
identifi
monitor
quantifi
biomolecul
develop
howev
develop
system
detect
viral
agent
difficult
especi
earli
stage
infect
advent
molecular
beacon
technolog
possibl
track
mrna
host
rsv
base
framework
modif
oligonucleotidefunction
gold
nanoparticul
probe
suggest
improv
wherein
gold
nanoparticl
function
dna
hairpin
structur
thiol
linkag
dna
design
loop
portion
complimentari
sequenc
rna
detect
stem
link
gold
nanoparticl
thiol
group
end
link
fluorophor
hybrid
target
rna
loop
fluorophor
goe
away
quench
gold
emiss
track
thu
live
imag
mrna
possibl
mechan
hairpin
dna
function
gold
nanoparticl
haunp
execut
jayagop
et
al
detect
rsv
mrna
cell
techniqu
offer
advantag
realtim
detect
multipl
mrna
time
includ
mrna
rsv
glyceraldehyd
dehydrogenas
cell
quantit
assay
use
approach
possibl
use
dna
hairpin
structur
function
gold
filament
immers
capillari
tube
contain
viral
rna
scan
fluoresc
setup
abl
detect
low
pfu
time
better
standard
comparison
elisa
immunofluoresc
microscopi
base
detect
rsv
direct
fluorescentantibodi
assay
dfa
consid
gold
standard
compar
efficaci
dfa
assay
seem
reach
consensu
prime
possibl
disadvantag
inconsist
dfa
attribut
fade
dye
conjug
antibodi
dye
limit
sensit
due
background
stain
excit
two
differ
wavelength
address
issu
fluoresc
nanoparticl
quantum
dot
qd
appear
promis
candid
field
clinic
diagnost
due
inorgan
natur
less
suscept
metabol
degrad
qd
photost
lose
fluoresc
long
exposur
light
excit
wavelength
radiat
differ
wavelength
henc
use
multiplex
variou
success
attempt
made
amelior
rsv
detect
use
qd
progress
rsv
infect
cell
line
studi
use
confoc
microscopi
qd
probe
f
g
protein
found
method
sensit
realtim
quantit
rtpcr
particularli
earli
infect
approach
use
tripp
et
al
vitro
vero
cell
line
extrapol
vivo
balbc
mice
studi
conclud
approach
beyond
diagnost
use
multiplex
viru
andor
host
cell
antigen
detect
intracellular
track
studi
flow
cytometri
wide
use
diagnost
reliabl
improv
million
cell
analyz
time
comprehens
data
produc
track
target
cellular
protein
eas
multipl
paramet
correl
allow
flow
cytometri
use
variou
qualit
quantit
assay
flow
cytomet
could
detect
rsv
sensit
reproduc
agraw
et
al
show
antibodi
conjug
qd
could
detect
rsv
rapidli
sensit
use
principl
microcapillari
flow
cytometri
integr
fixedpoint
confoc
microscop
singlemolecul
detect
carboxylatemodifi
fluoresc
nanoparticl
streptavidinco
qd
use
studi
could
estim
rel
level
surfac
protein
express
fda
approv
microarray
system
semiautom
respiratori
viru
nucleic
acid
test
vrnat
fulli
autom
respiratori
viru
nucleic
acid
test
sp
rvnatsp
nanospher
northbrook
il
exampl
microarray
base
detect
system
influenza
viru
influenza
b
viru
rsv
rsv
b
system
base
effici
detect
microarray
base
hybrid
use
gold
nanoparticl
hybrid
oligonucleotid
probe
target
dnarna
detect
specif
hybrid
gold
nanoparticl
function
oligonucleotid
signal
gener
gold
facilit
reduct
silver
presenc
reduc
agent
raman
spectroscopi
work
basi
inelast
scatter
monochromat
radiat
like
near
infrar
visibl
near
ultraviolet
interact
analyt
lowfrequ
vibrat
andor
rotat
energi
signal
gener
low
henc
signal
enhanc
use
silver
gold
matrix
substrat
mani
modif
raman
spectroscopi
wide
use
one
surfac
enhanc
raman
spectroscopi
ser
figur
b
direct
intrins
indirect
intrins
extrins
detect
three
major
ser
detect
configur
contrast
ir
spectroscopi
raman
spectra
obtain
without
interfer
water
molecul
thu
biolog
analyt
studi
nativ
conform
ser
routin
use
variou
bioanalyt
purpos
due
rapid
nondestruct
detect
analyt
sensit
specif
precis
even
singl
molecul
live
cell
ser
target
variou
analyt
may
constitut
dna
rna
protein
organ
compound
nucleic
acid
prefer
candid
biolog
ser
investig
influenc
base
composit
sequenc
conform
local
andor
global
nucleic
acid
intermolecular
dynam
protein
ligand
correspondingli
express
typic
spectral
signatur
bacteria
virus
variou
biolog
sampl
identifi
character
classifi
clinic
sampl
ser
distinguish
dna
rna
virus
like
adenoviru
rhinoviru
rotaviru
rsv
rotaviru
common
caus
gastroenter
children
rapid
sensit
detect
demonstr
ser
ser
establish
power
tool
sensit
expedit
specif
detect
variou
respiratori
pathogen
like
mycoplasma
pneumonia
rsv
use
silver
nanorod
array
na
platform
ser
differenti
pneumonia
cultur
spike
true
clinic
throat
swab
sampl
achiev
notabl
sensit
ser
resolv
strain
level
differ
rsv
strain
along
exploit
clinic
diagnosi
instrument
rsv
three
envelop
protein
f
g
sh
f
g
glycosyl
repres
target
neutral
antibodi
rsv
f
protein
emerg
good
vaccin
candid
due
conserv
vital
role
cell
attach
passiv
immun
direct
approach
counter
rsv
figur
initi
polyclon
antibodi
healthi
human
individu
resist
rsv
success
prevent
rsv
infect
high
risk
infant
pool
purifi
immunoglobin
popular
respigam
monoclon
antibodi
specif
neutral
f
protein
confer
effect
protect
rsv
compar
respigam
licens
monoclon
antibodi
palivizumab
synagi
use
passiv
protect
high
risk
infant
sever
diseas
thu
replac
respigam
efficaci
recombin
monoclon
antibodi
palivizumab
test
prophylaxi
therapi
immunocompromis
cotton
rat
repeat
dose
palivizumab
requir
prevent
rebound
rsv
replic
palivizumab
administ
alon
combin
aerosol
ribavirin
palivizumab
cure
treat
seriou
rsv
diseas
neutral
rsv
help
prevent
seriou
rsv
infect
motavizumab
found
neutral
rsv
bind
rsv
fusion
protein
f
attach
host
viral
transcript
viral
entri
inhibit
palivizumab
motavizumab
pretreat
rsv
reduct
viral
transcript
thu
inhibit
cellcel
viruscel
fusion
like
prevent
conform
chang
f
protein
need
viral
fusion
effect
use
palivizumab
limit
due
cost
use
infant
high
risk
bronchiol
base
coverag
differ
healthcar
system
spite
restrict
palivizumab
wide
societ
impact
use
infant
chronic
lung
diseas
due
prematur
birth
haemodynam
signific
cardiac
diseas
accord
modifi
recommend
committe
infecti
diseas
center
diseas
control
prevent
rsv
palivizumab
recommend
infant
congenit
heart
diseas
chd
chronic
lung
diseas
cld
birth
week
minimum
dose
recommend
irrespect
month
first
dose
geograph
locat
infant
gestat
age
week
day
week
day
without
hemodynam
signific
chd
cld
new
recommend
committe
aim
high
risk
group
includ
infant
attend
child
care
one
sibl
children
younger
year
live
child
also
infant
qualifi
receiv
prophylaxi
reach
day
age
palivizumab
although
effect
costli
thu
benefici
recipi
especi
period
rsv
circul
cost
effect
mean
produc
rsv
f
neutral
antibodi
experi
phage
plant
much
success
regard
palivizumab
product
observ
nicotiana
benthamiana
plant
system
offer
glycosyl
high
product
lower
upstream
equival
downstream
cost
compar
mammalian
deriv
palivizumab
efficaci
plant
deriv
palivizumab
mammalian
deriv
palivizumab
plant
deriv
human
monoclon
antibodi
cotton
rat
rsv
genom
code
structur
function
protein
immunogen
refer
vaccin
develop
rsv
dna
base
vaccin
develop
base
protein
concept
simpl
involv
dna
fragment
code
part
whole
protein
rsv
insert
appropri
express
plasmid
vector
constitut
promot
control
figur
initi
work
approach
success
express
cell
vivo
murin
model
elimin
rsv
infect
problem
rsv
associ
type
immun
respons
persist
problem
attempt
resolv
manipul
paramet
choic
protein
express
express
vector
adjuv
formul
intracellular
stabil
plasmid
mice
challeng
rsvg
construct
balanc
system
pulmonari
cytokin
rsv
neutral
antibodi
respons
howev
rsv
f
protein
gene
consid
wide
use
prospect
target
develop
vaccin
often
favourit
model
dna
vaccin
rsv
wild
type
rsv
f
protein
express
dna
plasmid
poorli
express
codon
optim
dna
vaccin
design
better
vivo
express
henc
immunogen
reduc
rsv
titer
address
low
immunogen
f
protein
antagonist
activ
rsv
ifn
immunopatholog
construct
design
insert
f
gene
newcastl
diseas
viru
ndv
vector
ndvf
modif
serv
purpos
higher
elicit
ifn
ndvf
rsv
protect
rsv
infect
without
immunopatholog
enhanc
adapt
immun
balbc
mice
wu
et
al
develop
dna
vaccin
strategi
rsv
use
mucos
adjuv
two
dna
vaccin
vector
name
contain
residu
rsv
f
gene
clone
dna
vaccin
vector
dna
vaccin
vector
contain
cholera
toxin
gene
region
call
act
mucos
adjuv
dna
vaccin
success
express
mous
muscl
tissu
confirm
immunohistolog
analysi
rtpcr
immun
mice
induc
neutral
antibodi
system
ab
igg
respons
mucos
antibodi
respons
ig
mimick
challeng
live
rsv
mice
immun
vector
contain
less
rsv
rna
lung
tissu
induc
higher
mix
cytokin
immun
respons
better
protect
immun
vector
confirm
lung
immunohistolog
studi
ration
approach
confer
protect
variou
pathogen
singl
vaccin
often
known
combin
composit
vaccin
employ
rsv
influenza
viru
infa
herp
simplex
viru
mice
immun
either
inject
gene
gun
gold
bead
carrier
plasmid
dna
mixtur
four
plasmid
infa
haemagglutinin
ha
infa
nucleoprotein
np
glycoprotein
gd
rsv
glycoprotein
f
led
protect
mice
respect
pathogen
challeng
addit
also
offer
protect
mycoplasma
pulmoni
challeng
well
recent
sever
develop
made
field
recombin
vaccin
one
approach
mycobacterium
bovi
bacillu
calmetteguerin
bcg
vaccin
modifi
carri
rsv
n
test
found
establish
type
immun
rsv
challeng
mice
recombin
vaccin
also
elicit
activ
rsv
specif
cell
produc
along
reduct
weight
loss
lung
viral
protein
load
thu
establish
immun
respons
bactofect
bacteria
mediat
transfer
plasmid
dna
mammalian
cell
xie
et
al
employ
interest
way
deliv
express
dna
vaccin
mice
rsv
approach
serv
purpos
natur
activ
immunostimulatori
respons
host
also
deliveri
dna
vaccin
attenu
salmonella
typhimurium
strain
express
vector
contain
rsv
f
gene
oral
administ
balbc
mice
trigger
effici
antigenspecif
humor
cellular
mucos
immun
novel
method
develop
rsv
dna
vaccin
devis
replac
structur
gene
rsv
gene
attenu
strain
venezuelan
equin
enceph
viru
veev
veev
ssrna
genom
contain
strong
subgenom
promot
replicon
particl
prepar
provid
helper
rna
encod
veev
capsid
envelop
glycoprotein
compris
structur
protein
transfect
vero
cell
result
replicon
particl
could
independ
synthes
rsv
protein
therebi
activ
immun
respons
protect
system
could
modul
administr
helper
rna
strategi
appli
mice
rhesu
monkey
model
confer
protect
rsv
desir
extent
balanc
type
immun
respons
receiv
sever
approach
consid
develop
effect
vaccin
rsv
includ
formalin
inactiv
rsv
vaccin
develop
late
instead
result
enhanc
infect
effici
rsv
vaccin
would
one
proper
balanc
immunogen
protect
without
allerg
respons
rsv
f
wide
accept
vaccin
candid
due
conserv
natur
among
variou
strain
well
among
paramyxovirus
antigen
region
correspond
rsv
f
protein
region
clone
vector
b
gene
cholera
toxin
name
elicit
helper
cell
type
immun
respons
mice
also
result
higher
express
serum
neutral
antibodi
immun
mice
similarli
multival
recombin
protein
develop
clone
rsv
f
g
protein
bacteri
vector
call
result
enhanc
serum
igg
titer
also
use
conjunct
flagellin
adjuv
increas
igg
titer
effort
address
issu
immunogen
sever
studi
use
approach
combin
virus
rsv
gene
one
studi
use
viru
like
particl
vlp
develop
np
protein
newcastl
diseas
viru
ndv
chimer
protein
consist
cytoplasm
transmembran
domain
ndv
hn
protein
ectodomain
rsv
g
protein
hg
vlp
result
immun
respons
better
uvinactiv
rsv
provid
complet
protect
mice
rsv
even
singl
dose
elicit
neutral
antibodi
vlphgimmun
mice
show
enhanc
patholog
compar
firsv
anoth
approach
solv
immunogen
relat
problem
devis
rsv
vaccin
recombin
vector
base
either
murin
piv
type
sendai
viru
use
deliv
rsv
g
protein
revers
genet
provid
effect
protect
rsv
cotton
rat
anoth
similar
studi
use
sendai
viru
sev
vaccin
carri
rsv
f
gene
provid
protect
four
pathogen
includ
mous
rsv
approach
use
compar
two
vaccin
model
one
sev
backbon
backbon
sev
base
vaccin
show
decreas
rsv
load
african
green
monkey
lung
titer
anoth
studi
recombin
vaccin
util
recombin
simian
varicella
virus
rsvv
express
rsv
g
protein
gene
evalu
vero
cell
line
recombin
vaccin
approach
could
use
elderli
peopl
risk
infect
varicella
rsv
well
children
chickenpox
rsv
rsvv
base
vaccin
result
enhanc
immun
respons
rsv
antigen
serv
suitabl
vaccin
rhesu
monkey
similar
approach
adopt
develop
recombin
alphaviru
immun
stimul
complex
iscom
antigen
rsv
recombin
vector
design
use
selfabort
alphaviru
call
semiliki
forest
viru
carri
rsv
f
g
gene
advantag
use
recombin
abort
virus
undergo
viral
infect
elimin
chanc
advers
effect
result
infect
infect
host
cell
result
express
insert
rsv
gene
follow
humor
cell
mediat
immun
respons
iscom
use
compos
quillaja
saponin
lipid
rsv
antigen
adjuv
properti
well
iscom
shown
enhanc
antibodi
product
cell
prolifer
mhc
classi
respons
well
rsv
specif
neutral
antibodi
igg
iga
recombin
vaccin
sfvf
sfvfg
result
ifn
gamma
respons
along
resist
rsv
infect
without
worsen
rsv
diseas
wherea
result
opposit
iscomfg
enhanc
goblet
cell
hyperplasia
postrsv
challeng
recent
sever
applic
nanotechnolog
appear
develop
vaccin
popularli
known
nanovaccin
dna
vaccin
prone
rapid
degrad
introduc
anim
system
increas
retent
increas
efficaci
dna
vaccin
encapsul
polym
protect
facilit
control
releas
figur
variou
synthet
natur
polym
experi
target
deliveri
control
releas
carrier
chitosan
polym
great
interest
respiratori
diseas
treatment
mucoadhes
properti
biodegrad
balanc
purpos
longer
retent
control
releas
carrier
molecul
encapsul
thu
chitosan
nanoparticl
develop
rsv
dna
vaccin
constitut
express
vector
consist
antigen
region
rsv
f
g
gene
driven
human
cytomegaloviru
promot
encapsul
use
chitosan
nanoparticl
dcnp
advantag
dcnp
stabl
nake
dna
chitosan
ideal
protect
dna
degrad
nucleas
sustain
dcnp
mice
nake
dna
correspondingli
indic
higher
rsv
protein
express
evid
immunohistochem
realtim
pcr
studi
similar
studi
conduct
eroglu
et
al
highli
conserv
rsv
f
gene
clone
express
vector
encapsul
polyhydroxyethylmethacryl
nanospher
coat
chitosan
transfect
cell
transfect
effici
system
par
commerci
avail
transfect
agent
vivo
studi
balbc
mice
also
indic
f
protein
express
reduc
rsv
infect
vaccin
base
recombin
rsv
n
gene
ring
call
nsr
enclos
bacteri
rna
develop
assess
intranas
balbc
mice
nsr
adjuv
e
coli
enterotoxin
lt
effici
protect
rsv
high
titer
iga
forth
although
nanovaccin
elicit
mild
inflammatori
respons
airway
mice
enhanc
express
antigen
specif
respons
anoth
novel
approach
nanoemuls
ne
use
adjuv
mucos
rsv
vaccin
mous
model
found
provid
signific
protect
rsv
along
rsv
specif
humor
respons
enhanc
respons
ne
render
rsv
ineffect
treat
hour
reduct
viral
titer
compar
media
control
nersv
also
led
higher
express
rsv
specif
antibodi
signific
decreas
viral
load
hyperreact
cytokin
induct
thu
novel
approach
seem
promis
safe
vaccin
option
rsv
bitter
episod
formalin
inactiv
rsv
vaccin
imped
vaccin
develop
fact
rais
seriou
concern
use
nativ
rsv
compon
approach
reviv
novelti
wherein
engin
rsv
f
protein
aggreg
form
nanoparticl
use
vaccin
nanoparticl
induc
protect
immun
cotton
rat
combat
rsv
host
neutral
antibodi
alway
prefer
therapeut
antibodi
epitop
neutral
antibodi
larger
therapeut
neutral
antibodi
palivizumab
motavizumab
thu
use
epitop
neutral
antibodi
vaccin
requir
retent
immuno
function
conform
get
rid
undesir
protein
rsv
f
oligomer
protein
nanoparticl
synthes
insert
recombin
rsv
f
gene
baculoviru
express
insect
cell
line
result
high
recombin
protein
express
compar
nativ
protein
also
result
conform
rosett
nanoparticl
aggreg
multipl
rsv
f
oligom
found
immunogen
studi
extrapol
phase
human
clinic
trial
show
safeti
efficaci
rsv
nutrit
consid
treatment
prerequisit
homeostasi
nutrit
imbal
attract
disord
diseas
supplementari
nutrient
could
revers
advers
effect
disord
diseas
sensu
nutrit
serv
treatment
prevent
carbohydr
rich
diet
diet
lack
antioxid
like
fruit
veget
pregnanc
suspect
rsv
suscept
resveratrol
polyphenol
grape
demonstr
reduct
rsv
replic
inflamm
studi
demonstr
cord
blood
defici
vitamin
associ
rsv
bronchiol
neonat
higher
risk
rsv
first
year
life
vitamin
inhibit
signal
respons
rsv
inflamm
without
affect
antivir
activ
host
lower
level
micronutri
like
zinc
copper
selenium
retinol
vitamin
alphatocopherol
vitamin
e
observ
children
affect
rsv
human
metapneumoviru
one
studi
rsv
infect
children
administ
vitamin
compens
lower
vitamin
serum
level
found
benefici
children
sever
rsv
infect
also
probiot
diet
shown
boost
resist
pathogen
modul
immun
respons
case
rsv
lactobacillu
rhamnosu
probiot
bacteria
treat
balbc
mice
show
significantli
reduc
lung
viral
load
patholog
rsv
challeng
studi
indic
import
associ
nutrit
rsv
suscept
ribavirin
hydroxymethyl
wide
use
broad
spectrum
synthet
antivir
drug
dna
rna
viru
treatment
oral
nasal
administr
ribavirin
treatment
sever
lower
respiratori
tract
infect
caus
rsv
influenza
viru
option
ribavirin
phosphoryl
cell
compet
viral
rnadepend
rna
polymeras
rna
virus
howev
mechan
ribavirin
differ
dna
virus
competit
inhibitor
inosin
monophosph
dehydrogenas
impdh
caus
delet
gtp
messeng
rna
mrna
guanylyl
transferas
mrna
cap
enzym
advers
affect
protein
synthesi
exact
mechan
antivir
activ
ribavirin
rna
dna
virus
still
clear
use
ribavirin
virus
due
antivir
activ
also
due
capabl
modul
immun
system
ribavirin
suggest
immunostimulatori
effect
th
cell
deriv
ribavirin
viramidin
merimepodib
impdh
inhibitori
molecul
like
mycophenol
mizoribin
shown
antivir
activ
hepat
c
viru
henc
scope
investig
potenti
antirsv
drug
mani
compound
inhibit
rsv
replic
wellknown
compound
rsv
e
urea
show
promis
result
rsv
deriv
antibiot
geldanamycin
target
cancer
attract
research
due
antivir
properti
compound
inhibitor
thu
help
rsv
rsv
depend
heat
shock
protein
replic
antirsv
activ
compound
seen
human
airway
epitheli
cell
haec
consid
drug
resist
therapeut
due
highli
conserv
target
chaperon
protein
compound
also
known
inhibit
replic
hpiv
influenza
viru
rhinoviru
antivir
activ
dose
toxic
cell
inhal
mode
treatment
increas
local
efficaci
avoid
unnecessari
exposur
organ
recent
advanc
develop
antivir
drug
includ
fusion
inhibitor
fusion
inhibitor
usual
synthet
compound
molecul
interrupt
fusion
viru
host
cell
usual
bind
fusion
protein
figur
fusion
inhibitor
wide
studi
antivir
agent
sever
virus
includ
hiv
rsv
henipaviru
hendra
viru
nipah
viru
paramyxoviru
metapneumovirus
hiv
rsv
first
report
use
peptid
fusion
inhibitor
includ
develop
synthet
peptid
base
leucin
zipper
region
hiv
fusion
glycoprotein
show
nm
fusion
inhibitor
paramyxovirus
also
develop
base
conserv
region
fusion
protein
f
f
protein
wide
known
conserv
natur
among
paramyxovirida
famili
lambert
et
al
develop
fusion
inhibitor
belong
conserv
heptad
repeat
hr
domain
region
f
protein
analog
peptid
hiv
fusion
inhibitor
test
rsv
human
parainfluenza
viru
measl
viru
show
antivir
activ
specif
speci
origin
fda
approv
antihiv
drug
intern
nonproprietari
name
inn
enfuvirtid
trade
name
fuzeon
peptid
test
peptid
develop
rsv
effect
fusion
inhibitor
character
test
shown
differ
fusion
inhibitor
deriv
hr
region
differ
antivir
activ
peptid
show
respect
rsv
similarli
anoth
peptid
inhibitor
develop
rhoa
show
inhibit
syncytia
format
induc
rsv
rhoa
small
gtpase
involv
mani
biolog
process
shown
bind
rsvf
protein
amino
acid
peptid
deriv
rsv
f
bind
domain
rhoa
shown
inhibit
rsv
infect
syncytium
format
block
celltocel
fusion
reduc
viral
titer
ill
mice
fusion
inhibitor
limit
peptid
inhibitor
rang
chemic
inhibitor
also
test
rsv
benzimidazol
wellknown
fusion
inhibitor
lead
compound
identifi
subsequ
synthes
analogu
low
molecular
weight
benzimidazol
show
high
antivir
activ
nm
time
better
ribavirin
compound
show
antifus
activ
rsv
dual
mode
action
includ
prevent
cellviru
fusion
activ
well
cellcel
fusion
activ
howev
found
ineffect
virus
famili
includ
measl
viru
vast
screen
mani
compound
sourc
chembionet
librari
conduct
antirsv
activ
vitro
two
novel
compound
n
triazolo
benzenesulfonamid
name
name
mine
reduc
viru
infect
valu
respect
recent
sever
group
report
synthet
fusion
inhibitor
rsv
especi
benzotriazol
deriv
evalu
structureact
relationship
sar
compound
name
seri
compound
observ
topolog
side
chain
compound
import
facilit
modif
physic
properti
mani
compound
show
poor
therapeut
indic
cytotox
effect
host
cell
test
order
address
issu
second
seri
deriv
compound
develop
evalu
sar
function
fusion
inhibitor
compound
develop
toler
diethylaminoethyl
side
chain
polar
nonpolar
function
rsv
replac
benzotriazol
potent
inhibitor
rsv
vitro
compound
name
addit
structur
vector
absent
account
enhanc
potenc
fusion
inhibitor
serv
base
develop
fusion
inhibitor
group
compound
modifi
introduc
acid
basic
function
group
side
chain
oxadiazolon
antirsv
activ
compar
ribavirin
wherea
ester
modifi
group
compound
suitabl
oral
administr
studi
led
identif
deriv
call
oral
activ
rsv
inhibitor
anoth
compound
studi
analogu
potent
antirsv
activ
toward
resist
rsv
compound
modifi
side
chain
introduct
aminomethyl
substitu
core
benzimidazol
moieti
aminomethyl
substitut
benzimidazol
ring
found
enhanc
antivir
activ
furthermor
consecut
modif
benzimidazol
result
benzimidazoleisatin
oxim
evalu
antirsv
activ
compound
analyz
antivir
activ
cell
permeabl
metabol
stabil
human
live
microsom
sever
deriv
modif
oalkyl
addit
nitrogen
atom
isatin
phenyl
ring
implement
also
enhanc
antivir
activ
three
compound
shown
antivir
activ
rsv
balbc
mice
compound
identifi
found
potent
antirsv
agent
inhibit
rsv
vitro
vivo
phase
clinic
trial
biphenyl
triazin
synthes
coupl
diaminobiphenyl
two
chlorotriazin
molecul
microwav
condit
found
effect
laboratori
clinic
virus
concentr
mm
mgml
compound
reduc
viral
load
extent
log
african
green
monkey
model
also
mice
cotton
rat
order
enhanc
antivir
activ
modifi
replac
triazin
linker
pyrimidin
howev
modif
much
differ
antivir
activ
thu
render
modif
much
practic
use
sever
novel
nonbenzimidazol
base
compound
show
antirsv
activ
vitro
polar
compound
thiazoleimidazol
select
compound
potenc
moder
permeabl
low
metabol
rate
rat
detail
vivo
studi
anticip
establish
metal
like
silver
gold
antimicrobi
activ
cytotox
effect
reactiv
metal
make
unsuit
use
human
reactiv
behaviour
metal
modul
reduc
size
nanoscal
carbon
nanotub
cnt
emerg
nanomateri
biomed
applic
polyvinylpyrrolidon
pvp
conjug
silver
nanoparticl
show
low
toxic
cell
low
concentr
exhibit
rsv
inhibit
figur
singh
et
al
use
fusion
inhibitor
peptid
function
gold
nanoparticl
carboxyl
gold
nanoparticl
size
nm
rsv
show
inhibit
rsv
respect
similar
approach
employ
recombin
rsv
f
protein
function
gold
nanorod
emerg
nanotechnolog
open
new
avenu
rsv
treatment
rna
interfer
rnai
normal
cellular
event
becom
power
mean
control
gene
regul
interfer
mediat
sirna
use
human
immunodefici
viru
polioviru
hepat
c
parainfluenza
viru
piv
cell
cultur
concept
inhibit
rsv
infect
use
target
antisens
mechan
appli
jairath
et
al
silenc
gene
follow
rnai
approach
bitko
et
al
design
sirna
p
gene
rsv
piv
protect
mice
individu
mix
infect
upon
intranas
administr
effect
sirna
action
observ
without
use
transfect
reagent
approach
also
effect
target
rsvf
gene
similar
work
cell
line
replic
use
four
sirna
design
silenc
rsv
f
gene
show
inhibitori
action
rsv
variou
concentr
silenc
differ
rsv
gene
inhibitori
action
rsv
plasmid
encod
sirna
complex
chitosan
target
gene
decreas
rsv
infect
balbc
mice
fischer
rat
also
reduc
associ
inflamm
zhang
et
al
show
sirna
nanoparticl
target
rsv
gene
result
increas
ifninduc
gene
cell
human
dendrit
cell
elev
ifn
increas
differenti
cell
cell
also
mice
treat
nanoparticl
exhibit
signific
decreas
lung
viral
titer
inflamm
interferoninduc
enzym
rnase
present
higher
vertebr
requir
oligoadenyl
endoribonucleas
activ
singlestrand
rna
featur
rnase
look
upon
effect
rsv
treatment
rsv
upon
infect
elicit
immun
respons
host
particularli
interferon
level
phenomenon
exploit
antirsv
activ
rnasel
endoribonucleas
activ
rnasel
use
target
rsv
gene
specif
coval
oligoadenyl
target
antisens
result
reduct
rsv
replic
endoribonucleas
activ
neglig
effect
inact
dimer
form
link
antisens
link
random
sequenc
nucleotid
antisens
molecul
lack
affect
rsv
cellular
rna
addit
widen
rang
approach
effect
modif
oligonucleotid
rna
target
site
studi
model
improv
respect
specif
activ
chimera
christen
sequenc
inform
rsv
genom
use
develop
potent
rsv
strain
ribavirin
administr
sirna
combin
ribavirin
recommend
effect
treatment
parent
molecul
chemic
modifi
increas
vivo
stabil
specif
potenc
result
new
version
effect
parent
molecul
rsv
strain
b
cytotox
effect
dose
rang
treatment
african
green
monkey
show
promis
result
alvarez
cowork
came
new
gene
specif
sirna
broad
spectrum
antivir
activ
target
nucleocapsid
gene
rsv
vivo
balbc
murin
studi
demonstr
intranas
dose
result
reduct
rsv
lung
concentr
scale
molecul
rsv
treatment
human
safeti
toler
pharmacokinet
test
healthi
adult
demonstr
safeti
toler
human
subject
human
clinic
trial
healthi
subject
group
administ
either
placebo
nasal
spray
rsv
reduct
rsv
infect
subject
receiv
without
advers
effect
thu
studi
real
term
establish
uniqu
proofofconcept
rnai
therapeut
agent
rsv
treatment
prove
safe
effect
rsv
even
complex
clinic
situat
like
lung
transplant
remark
achiev
product
alnylam
pharmaceut
inc
complet
phase
iib
clinic
trial
anoth
approach
rnai
treatment
combat
rsv
deceler
advers
effect
rsv
mediat
type
immun
respons
aggrav
host
immun
respons
harm
rsv
infect
particularli
neonat
rsv
bronchiol
increas
level
result
increas
respons
antisens
oligom
synthesis
local
silenc
gene
intranas
applic
antisens
oligom
neonat
murin
model
reduc
type
mediat
pulmonari
patholog
sign
inflamm
lung
dysfunct
combinatori
approach
antisens
oligom
rsv
would
control
rsv
infect
advers
effect
rsv
mediat
inflamm
phosphorodiamid
morpholino
oligom
pmo
oligom
nucleobas
coval
attach
morpholin
ring
replac
deoxyribos
sugar
phosphodiest
bond
replac
phosphorodiamid
linkag
morpholino
chemic
modif
rna
use
antisens
advantag
specif
vivo
stabil
target
deliveri
pmo
block
target
complementari
rna
target
rna
fail
interact
protein
thu
rna
function
hinder
specif
true
mrna
translat
phenomenon
differ
antisens
rnase
h
involv
henc
pmo
design
contain
initi
codon
virus
antivir
better
intak
cell
vivo
system
facilit
conjug
cell
penetr
peptid
argininerich
peptid
rxr
approach
attempt
rsvl
gene
inhibit
rsv
cellular
murin
model
variou
natur
synthet
chemic
compound
screen
applic
treat
rsv
infect
plant
rich
sourc
alkaloid
steroid
flavonoid
complex
compound
medicin
valu
medicin
plant
contribut
significantli
tradit
indian
chines
medicin
ancient
chines
literatur
descript
plant
extract
respiratori
diseas
exact
activ
compound
action
tradit
formul
understood
modern
assay
made
possibl
get
insight
mechan
purif
activ
plant
base
compound
extract
lonicera
deflexicalyx
chin
jinyinhua
test
rsv
activ
compound
extract
acid
cj
isol
purifi
seri
chromatograph
process
suggest
cj
fusion
inhibitor
vitro
vivo
studi
suggest
effect
rsv
inhibitor
ribavirin
cytopath
effect
cpe
assay
base
screen
show
herb
moder
potent
antirsv
activ
plant
extract
cinnamomum
cassia
cimicifuga
foetida
shengmagegentang
smggt
shomakakkonto
xiaoqinglongtang
shoseiryuto
socheongryongtang
gegentang
ginger
zingib
officinal
show
antirsv
activ
extract
probabl
inhibit
rsv
infect
block
f
protein
bind
cell
extract
even
stimul
product
decoct
like
modifi
dingchuan
consist
salvia
miltiorrhiza
radix
scutellaria
radix
farfara
flo
ephedra
herba
liuhetang
consist
plant
extract
water
extract
licoric
radix
glycyrrhiza
radix
glycyrrhiza
preparata
shown
effect
rsv
vitro
moreov
modifi
dingchuan
decoct
mdd
exhibit
antiinflammatori
antivir
effect
mice
spf
icr
mice
infect
rsv
mdd
suppress
eotaxin
level
serum
mrna
express
lung
rsv
infect
mice
technolog
provid
enough
capabl
detect
rsv
variou
sampl
type
variou
stage
infect
use
array
techniqu
challeng
avail
facil
correct
time
reason
cost
import
perspect
rsv
diagnosi
strateg
manag
choic
point
care
test
central
laboratori
test
though
point
care
test
give
rapid
detect
advantag
suffer
lower
sensit
thu
problem
dealt
rapid
diagnost
tool
like
rtpcresim
microarray
base
semiautom
respiratori
viru
nucleic
acid
test
vrnat
fulli
autom
respiratori
viru
nucleic
acid
test
sp
rvnatsp
nanospher
northbrook
il
prove
effici
applic
routin
clinic
practic
still
challeng
numer
molecul
potenti
antivir
drug
screen
vast
number
compound
cumbersom
henc
high
throughput
filter
essenti
part
drug
develop
exampl
compound
molecular
librari
small
molecul
repositori
screen
rsv
cell
line
compound
show
inhibit
cytopath
effect
challeng
sophist
screen
translat
drug
clear
phase
vivo
anim
studi
human
trial
setback
develop
therapi
rsv
lack
good
anim
model
truli
manifest
effect
rsv
infect
human
rsv
experi
variou
anim
model
like
balbc
mice
cotton
rat
macaqu
african
green
monkey
owl
monkey
cebu
monkey
bonnet
monkey
oliv
baboon
chimpanze
evid
literatur
small
anim
model
like
balbc
mice
cotton
rat
commonli
use
due
eas
handl
low
cost
wherea
primat
studi
conduct
stringent
regul
bear
heavi
expens
mani
aspect
need
address
challeng
vaccin
develop
program
technolog
intervent
deal
rsv
challeng
includ
safeti
issu
concern
subject
involv
clinic
trial
evid
failur
formalin
inactiv
rsv
vaccin
motavizumab
clinic
trial
level
result
undesir
immunogen
respons
patient
involv
though
present
data
conclud
rsv
one
lead
caus
morbid
mortal
children
elder
signific
correl
increas
diseas
sever
respiratori
death
detect
respiratori
virus
situat
intric
author
report
coinfect
nonrsv
respiratori
virus
tend
increas
rsv
sever
also
hypothesi
synergist
associ
rsv
viral
bacteri
infect
thu
topic
subject
debat
contradict
need
clarif
consensu
proper
treatment
option
link
atopi
asthma
rsv
suspect
long
time
support
evid
possibl
relationship
also
ascrib
partli
genet
factor
rsv
host
activ
rsv
commun
may
affect
mani
factor
includ
climat
air
pollut
raceethn
social
behavior
popul
complex
factor
associ
rsv
establish
earli
detect
risk
factor
medic
intervent
reduc
incid
rsv
balanc
execut
andor
abey
prophylact
measur
critic
respect
discuss
determin
limit
data
correl
rsv
global
transmiss
dynam
climat
popul
due
difficult
develop
strategi
rsv
prevent
treatment
current
vaccin
effect
treatment
rsv
rapid
sensit
rsv
detect
possibl
detect
techniqu
amelior
incorpor
one
method
advanc
materi
scienc
biophys
capabl
reinforc
develop
design
rsv
detect
system
howev
effect
detect
techniqu
transform
effect
diagnosi
integr
commun
health
monitor
program
reason
cost
prevent
rsv
infect
present
limit
high
risk
individu
limit
efficaci
new
prevent
measur
research
like
dna
vaccin
subunit
vaccin
nanovaccin
reach
anim
trial
hand
rsv
treatment
approach
use
antisens
oligom
fusion
inhibitor
benzimidazol
drug
proceed
clinic
trial
challeng
associ
rsv
manag
categor
numer
howev
current
pace
scientif
research
develop
implement
scientif
commerci
program
recommend
develop
epidemiolog
strategi
seem
optimist
effect
diagnosi
prevent
treatment
solut
rsv
near
futur
